Clinical trials: Prostatic Neoplasm
Prostatic Neoplasm, Osteoporosis
Exercise for Physical Health in Men With Prostate Cancer
The purpose of this study is to conduct a 12-month randomized controlled trial comparing the effects of strength and impact exercise training to flexibility/relaxation training on body composition (bone, muscle and fat mass)…
- Trial name
- NCT00660686
- Testing
- Resistance Exercise, Flexibility Training
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Comprehensive Assessment of Cancer Theranostic Response
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study.
- Trial name
- TRAQinform (NCT06815354)
- Testing
- TRAQinform Theranostics
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- AIQ Solutions
Metastatic Castration-Resistant Prostate Cancer
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
- Trial name
- ENZA-p (NCT04419402)
- Testing
- Lu-PSMA, Enzalutamide
- Where
- 15 sites in Australia
- Volunteers
- 162 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Prostate Cancer
Prehabilitation in Prostate Cancer Patients, TelePrehabTrial
Localized prostate cancer is commonly treated with radical prostatectomy (RP). Following surgery adverse effects such as urinary incontinence, erectile dysfunction associated with decreased quality of life and decreased physical…
- Trial name
- NCT05608746
- Testing
- Physical Exercise, Pelvic Floor exercise, Sexual counseling
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- University of Aarhus
Prostate Cancer Patients
C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer
Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease planning to undergo Ra-223 therapy may be eligible for this study.
- Trial name
- NCT02715583
- Testing
- 11C-Acetate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Prostate Cancer
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy…
- Trial name
- NCT05477823
- Testing
- External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Evaluation of Fapi-pet in Prostate Cancer.
The investigators explore the biodistribution of FAPI-PET expression in primary high-risk prostate cancer in men undergoing RALP and eLND and in men with metastatic PCa about to start next generation antiandrogen.
- Trial name
- FAPIPETPCA (NCT05192694)
- Testing
- Computed tomography
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Helsinki University Central Hospital
Prostatic Neoplasms
Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer
To improve radiation therapy of prostate cancer, the investigators must be able to accurately identify the tumour. By using advanced functional imaging techniques available on state-of-the-art MRI scanners to clearly show the…
- Trial name
- NCT01976962
- Testing
- Stereotactic body RT with MR-guided boost
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- CancerCare Manitoba
Urinary Bladder Neoplasms, Prostatic Neoplasms
Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supreme™
The purpose of the present study is to compare the effect of PEEP on arterial oxygen partial pressure in elderly patients undergoing urologic surgery using LMA supreme™ in a lithotomy position.
- Trial name
- NCT03390127
- Testing
- PEEP
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Asan Medical Center
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating persons with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03805594
- Testing
- Lutetium Lu 177-PSMA-617, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, Oligometastasis
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients
Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden.
- Trial name
- OLIGOPELVIS2 (NCT03630666)
- Testing
- IADT, IADT + radiotherapy
- Where
- 16 sites in France
- Volunteers
- 256 people
- Sponsor
- Institut Cancerologie de l'Ouest
Advanced Prostate Cancer, Metastatic Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low…
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT06062745
- Testing
- 18F-fluciclovine, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen
Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer
The purpose of this study is to analyze heterogeneity of prostate cancer（PCa）based on the head-to-head imaging of prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) positron emission tomography computed…
- Conditions
- Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen, Positron Emission Tomography (PET)
- Trial name
- NCT06919159
- Testing
- PSMA PET/CT scan, FDG-PET
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiequn Yu
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer
This phase 1b trial is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) and pembrolizumab in patients with metastatic castration…
- Trial name
- LumOnate (NCT07090369)
- Testing
- Olaparib (300 mg BID), Pembrolizumab, 177Lu-PSMA-I&T
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce…
- Trial name
- NCT06496256
- Testing
- Barrigel, Transrectal Ultrasound
- Where
- 13 sites in United States, Australia
- Volunteers
- 84 people
- Sponsor
- Palette Life Sciences, Inc.
Prostate Cancer
Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients
The purpose of this study is to determine whether pre-operative prostate artery embolization (PAE) reduces intra-operative blood loss and improves surgical outcomes among prostate cancer patients undergoing robot-assisted…
- Trial name
- NCT02173522
- Testing
- Prostate artery embolization (PAE)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shivank Bhatia
Prostate Cancer, Erectile Dysfunction
A Bio-psychosocial Sexual Health Intervention for Prostate Cancer Survivors and Partners: a Feasibility Study
The burden of sexual dysfunction after prostate cancer surgery is responsible for the single greatest impact on patient/partner health-related quality of life; substantially more so than concern for cancer recurrence, or any…
- Conditions
- Prostate Cancer, Erectile Dysfunction, Sexual Dysfunction
- Trial name
- BSHR (NCT02640131)
- Testing
- Biomedical Component, Psychosocial Component, Attention Control
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- University Health Network, Toronto
Prostatic Neoplasms
Far Infrared Radiation Treatment for Prostate Cancer
A study to determine the use of far infrared radiation for the treatment of prostate cancer.
- Trial name
- NCT00573820
- Testing
- Far Infrared Radiation
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- GAAD Medical Research Institute Inc.